Evidence map›Paper›PMID 42818066›Full record

ArticlebioRxiv : the preprint server for biology2026

AR-V7 Utilizes a Noncanonical Nuclear Localization Signal to Sustain Androgen-Independent Nuclear Import and Signaling.

Urko Del Castillo, Naira E Abou-Ghali, Colin Burdette, Michelle Naidoo, CheukMan C Au, Kiran Kumari Sahu, Xuanrong Chen, Xi Kathy Zhou, Jacob Geri, Paraskevi Giannakakou

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Urko Del CastilloDepartment of Medicine, Division of Hematology Oncology, Weill Cornell Medicine. New York, NY 10065, USA.
Naira E Abou-GhaliDepartment of Medicine, Division of Hematology Oncology, Weill Cornell Medicine. New York, NY 10065, USA.
Colin BurdetteDepartment of Pharmacology, Weill Cornell Medicine. New York, NY 10065, USA.
Michelle NaidooDepartment of Medicine, Division of Hematology Oncology, Weill Cornell Medicine. New York, NY 10065, USA.
CheukMan C AuDepartment of Medicine, Division of Hematology Oncology, Weill Cornell Medicine. New York, NY 10065, USA.
Kiran Kumari SahuDepartment of Medicine, Division of Hematology Oncology, Weill Cornell Medicine. New York, NY 10065, USA.
Xuanrong ChenSandra and Edward Meyer Cancer Center, Weill Cornell Medicine. New York, NY 10065, USA.
Xi Kathy ZhouDepartment of Population Health Sciences, Division of Biostatistics, Weill Cornell Medicine. New York, NY 10065, USA.
Jacob GeriDepartment of Pharmacology, Weill Cornell Medicine. New York, NY 10065, USA.
Paraskevi GiannakakouDepartment of Medicine, Division of Hematology Oncology, Weill Cornell Medicine. New York, NY 10065, USA.

Funding

CANCER PHARMACOLOGYT32CA062948 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI LORRAINE J GUDAS · 1994 to 2026
$12.1M
Enhancing the Efficacy of Docetaxel in Prostate CancerR01CA266704 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI Steven P. Balk, PARASKEVI GIANNAKAKOU · 2022 to 2026
$3.2M
Predoctoral Training in Pharmacological SciencesT32GM141949 · NIGMS · WEILL MEDICAL COLL OF CORNELL UNIV · PI Kristen Elizabeth Pleil · 2021 to 2026
$2.5M
Supplement for Optically Gated Discovery of Protein-Biomolecule Interactions project.R35GM147449 · NIGMS · WEILL MEDICAL COLL OF CORNELL UNIV · PI Jacob Geri · 2022 to 2026
$2.4M
Molecular and Translational Oncology ResearchT32CA203702 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI BLENIS, JOHN, GIANNAKAKOU, PARASKEVI · 2017 to 2021
$1.4M
MBD4 Driven AR Reprogramming and Luminal Lineage Specification in Prostate CancerK99CA312863 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI Xuanrong Chen · 2026 to 2026
$152k
NCI NIH HHS K99 CA312863NCI NIH HHS R01 CA266704NCI NIH HHS T32 CA062948NCI NIH HHS T32 CA203702NIGMS NIH HHS R35 GM147449NIGMS NIH HHS T32 GM141949
6 · The paper itself

Abstract

AR-V7 is the most prevalent androgen receptor splice variant in metastatic castration-resistant prostate cancer, yet how it enters the nucleus independently of androgen binding has remained unclear. We previously demonstrated that AR-V7 undergoes nuclear import via a non-canonical pathway distinct from the microtubule-based, importin-α/β- and Ran-dependent mechanism used by full-length AR. Here, using systematic truncation and alanine-scanning mutagenesis, we identify a non-classical nuclear localization motif at the junction of the DNA-binding domain (DBD) and cryptic exon 3 (CE3) that is required for efficient AR-V7 nuclear import. Specific basic residues within the DBD and CE3 are required not only for nuclear entry but also for transcriptional activity. Unexpectedly, mutants retaining partial nuclear localization were transcriptionally silent, suggesting that CE3 contributes to transcriptional engagement through mechanisms separate from nuclear transport. Genome-wide transcriptomic analysis of a strongly import-deficient mutant confirmed that disruption of nuclear entry abolishes the AR-V7 transcriptional program. To map compartment-specific protein interactions, we applied antibody-guided photocatalytic proximity labeling. Nuclear AR-V7 associated most prominently with both canonical BAF and PBAF SWI/SNF chromatin remodeling complexes, together with known transcriptional coregulators and DNA-repair factors, whereas the cytoplasm-restricted mutant engaged different networks centered on mRNA deadenylation and decay, cytoskeletal regulation, and chaperone systems. Together, these findings define a variant-specific NLS, separate nuclear import from CE3-dependent transcriptional competence, and identify the cytoplasmic networks that become accessible when AR-V7 nuclear entry is impaired. They reveal two mechanistically distinct vulnerabilities for suppressing AR-V7 signaling: blocking nuclear translocation and disrupting CE3-dependent transcriptional engagement within the nucleus.

Indexed as

androgen receptor splice variantBiological Sciences / Medical Sciencescastration-resistant prostate cancercryptic exon 3nuclear importproximity labeling

Identifiers

PMID42818066
PMCPMC13622214

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.